UCB Ventures

About The Fund

UCB Ventures is a strategic corporate venture fund with a focus on transformative and innovative therapeutics and technology platforms. Established in 2017 and based in Brussels, Belgium, the fund concentrates on early-stage, high-risk opportunities in areas complementary to UCB's therapeutic expertise, which includes neurology/neurodegenerative diseases, immunology, and muscular-skeletal/bone health. They invest primarily in startups and early-stage companies in the US and Europe, expanding UCB's ability to generate value from novel technologies and insights that can significantly impact patients with severe diseases. UCB Ventures is an evergreen fund, meaning they reinvest returns to sustain their investment activities over time. Their investment strategy reflects their dedication to finding and supporting breakthrough innovations in next-generation cell and gene therapy, regenerative medicine, cell and tissue homeostasis, and RNA modulation. They also invest in oligo-based and synthetic biology therapeutics. UCB Ventures distinguishes themselves with their speed and agility, combined with a thoughtful and sophisticated approach to their investments. They are committed to being long-term partners, collaborating closely with entrepreneurs to maximize the potential of their portfolio companies. The fund manages assets of $150 million and specializes in equity investments, leveraging their industry knowledge to support companies in the Biotech and Medical Devices sectors as well as Hospital Services and Life Science in general. With a presence in both Europe and the US, particularly with a regional office in London, England, they maintain a global perspective while nurturing their investments towards growth and innovation. UCB Ventures holds themselves accountable to high ethical standards, committed to driving science forward for the betterment of patients' lives.